Amgen Inc. cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit. The world's biggest biotech drugmaker by revenue said it's starting a cycle of several important new product launches - big enough that last year it announced major job reductions and other cost cuts to free up money for the launches.